This is not legalization. But it is another major signal that ibogaine is now being taken seriously at the highest levels of government.
Following President Trump’s April 18 executive order on psychedelic-assisted therapies, the White House published an official release highlighting support from veterans’ groups, advocacy organizations, industry leaders, and policymakers. Among those quoted was Beond co-founder and CEO Tom Feegel.
In the White House release, Tom stated:
“We commend President Donald J. Trump and Health and Human Services Secretary Robert F. Kennedy, Jr. for their visionary leadership in urgently advancing a forward-looking, science-driven approach to mental health. This Executive Order signals that psychedelics, in particular ibogaine, are now taken seriously at the highest levels of government, not as a fringe concept, but as a component of the United States’ mission to lead the world in the development of the most advanced, outcomes-driven approach to mental health.”
That recognition matters.
For years, ibogaine has remained outside the mainstream U.S. medical system, despite growing attention from veterans, researchers, and patients seeking options beyond conventional treatment. The White House release reinforces that this conversation is no longer confined to the margins. It is now part of a broader national discussion around mental health innovation, veteran care, addiction, and treatment-resistant conditions.
This matters most for the people who have run out of options: veterans living with PTSD and TBI, individuals struggling with opioid dependency, and patients for whom standard approaches have repeatedly fallen short.
The executive order does not change what ibogaine is, and it does not make ibogaine fully approved in the United States overnight.
But it does help create a clearer federal pathway for research, evaluation, and future access, while signaling a much higher level of institutional seriousness than this field has previously received.
The work now is to ensure that this momentum moves forward with the rigor it deserves: grounded in science, guided by medical standards, and centered on patient safety.
